抗血管内皮生长因子(VEGF)时代的早产儿视网膜病变评估与管理
本文综述抗VEGF时代早产儿视网膜病变(ROP)的评估与管理进展,包括影像技术、远程医疗和人工智能辅助筛查,以及GEN-ROP网络培训模块。抗VEGF药物治疗严重ROP的证据增多,但玻璃体腔注射可致全身VEGF抑制至少1-12周,存在眼部及全身发育不良影响顾虑。未来研究应聚焦低成本眼底成像、人工智能平台、优化抗VEGF治疗算法及长期效应评估。
要点
- 抗VEGF药物治疗严重ROP的证据不断增多,但玻璃体腔注射可致全身VEGF抑制至少1-12周。
- 影像技术、远程医疗和人工智能辅助筛查为眼科医生短缺地区改善ROP诊疗创造机会。
- GEN-ROP创建网络远程教育培训模块,可培训包括非医师筛查者在内的所有ROP相关人员。
核心结论
- 抗VEGF药物用于严重ROP治疗的证据不断增多,但需关注其全身VEGF抑制及长期眼部和全身发育影响。
研究设计与样本
- 综述,检索范围未在摘要中报告。
主要发现
- 过去50年严重ROP治疗从有限手段演变为冷冻治疗和激光光凝,近期抗VEGF药物证据增多。
- 玻璃体腔抗VEGF治疗可导致全身VEGF抑制持续至少1-12周。
- GEN-ROP创建了可培训所有ROP相关人员(含非医师筛查者)的网络远程教育培训模块。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The incidence of retinopathy of prematurity (ROP) continues to rise due to the improved survival of very low birth weight infants in developed countries. This epidemic is also fueled by increased survival of preterm babies with variable use of oxygen and a lack of ROP awareness and screening services in resource-limited regions. Improvements in technology and a basic understanding of the disease pathophysiology have changed the way we screen and manage ROP, educate providers and patients, and improve ROP awareness. Advancements in imaging techniques, expansion of telemedicine services, and the potential for artificial intelligence-assisted ROP screening programs have created opportunities to improve ROP care in areas with a shortage of ophthalmologists trained in ROP. To address the gap in provider knowledge regarding ROP, the Global Education Network for Retinopathy of Prematurity (GEN-ROP) created a web-based tele-education training module that can be used to educate all providers involved in ROP, including non-physician ROP screeners. Over the past 50 years, the treatment of severe ROP has evolved from limited treatment modalities to cryotherapy and laser photocoagulation. More recently, there has been growing evidence to support the use of anti-vascular endothelial growth factor (VEGF) agents for the treatment of severe ROP. However, VEGF is known to be important in organogenesis and microvascular maintenance, and given that intravitreal anti-VEGF treatment can result in systemic VEGF suppression over a period of at least 1-12 weeks, there are concerns regarding adverse effects and long-term ocular and systemic developmental consequences of anti-VEGF therapy. Future research in ophthalmology to address the growing burden of ROP should focus on cost-effective fundus imaging devices, implementation of artificial intelligence platforms, updated treatment algorithms with optimal use of anti-VEGF and careful investigation of its long-term effects, and surgical options in advanced ROP. Addressing these unmet needs will aid the global effort against the ROP epidemic and optimize our understanding and treatment of this blinding disease.
引用
- Tsai AS, Chou HD, Ling XC, et al. Assessment and management of retinopathy of prematurity in the era of anti-vascular endothelial growth factor (VEGF). Prog Retin Eye Res. 2021. PMID: 34763060. doi:10.1016/j.preteyeres.2021.101018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。